It's now clear that the Supreme Court's ruling in Dobbs last year raised more questions than it answered. The latest example of this came late last Friday when a pair of opinions from federal judges threw the legality of a long-used abortion medication into doubt.

A judge from Washington state ordered the FDA to maintain the status quo for the drug mifepristone. Another judge from Texas came to the opposite conclusion, ordering the FDA to take mifepristone off the market despite the drug having won approval more than 20 years ago.

Bloomberg Law reporter Celine Castronuovo walks us through these developments and looks at what's coming in the fight over abortion—including another likely ruling from the Supreme Court—on the latest episode of our weekly podcast, On The Merits.

Do you have feedback on this episode of On The Merits? Give us a call and leave a voicemail at 703-341-3690.